Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of NewAmsterdam Pharma Company NV (NASDAQ: NAMS) was $19.46 for the day, down -1.96% from the previous closing price of $19.85. In other words, the price has decreased by -$1.96 from its previous closing price. On the day, 0.71 million shares were traded. NAMS stock price reached its highest trading level at $19.85 during the session, while it also had its lowest trading level at $19.22.
Ratios:
Our analysis of NAMS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 19.98 and its Current Ratio is at 19.98. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on June 17, 2025, initiated with a Buy rating and assigned the stock a target price of $42.
On June 10, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $44.
On June 04, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $42.Cantor Fitzgerald initiated its Overweight rating on June 04, 2025, with a $42 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 24 ’25 when Topper James N bought 2,520 shares for $18.43 per share. The transaction valued at 46,454 led to the insider holds 3,024,873 shares of the business.
Topper James N bought 1,260 shares of NAMS for $23,012 on Jun 25 ’25. The Director now owns 3,026,133 shares after completing the transaction at $18.26 per share. On Jun 16 ’25, another insider, Kling Douglas F, who serves as the Chief Operating Officer of the company, sold 100,000 shares for $19.29 each. As a result, the insider received 1,929,141 and left with 44,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAMS now has a Market Capitalization of 2184793600 and an Enterprise Value of 1225133952. For the stock, the TTM Price-to-Sale (P/S) ratio is 46.35 while its Price-to-Book (P/B) ratio in mrq is 2.81. Its current Enterprise Value per Revenue stands at 25.989 whereas that against EBITDA is -6.462.
Stock Price History:
The Beta on a monthly basis for NAMS is -0.03, which has changed by -0.02700001 over the last 52 weeks, in comparison to a change of 0.11708844 over the same period for the S&P500. Over the past 52 weeks, NAMS has reached a high of $27.29, while it has fallen to a 52-week low of $14.06. The 50-Day Moving Average of the stock is 2.98%, while the 200-Day Moving Average is calculated to be -4.11%.
Shares Statistics:
NAMS traded an average of 845.96K shares per day over the past three months and 920060 shares per day over the past ten days. A total of 112.17M shares are outstanding, with a floating share count of 62.20M. Insiders hold about 44.60% of the company’s shares, while institutions hold 57.45% stake in the company. Shares short for NAMS as of 1749772800 were 6970274 with a Short Ratio of 8.24, compared to 1747267200 on 6698285. Therefore, it implies a Short% of Shares Outstanding of 6970274 and a Short% of Float of 7.4099995000000005.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Currently, 11.0 analysts are dedicated to thoroughly evaluating and rating the performance of NewAmsterdam Pharma Company NV (NAMS) in the stock market.The consensus estimate for the next quarter is -$0.4, with high estimates of -$0.15 and low estimates of -$0.56.
Analysts are recommending an EPS of between -$1.31 and -$1.99 for the fiscal current year, implying an average EPS of -$1.59. EPS for the following year is -$1.82, with 11.0 analysts recommending between -$1.39 and -$2.6.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for NAMS’s current fiscal year. The highest revenue estimate was $46.53M, while the lowest revenue estimate was $2.59M, resulting in an average revenue estimate of $17.56M. In the same quarter a year ago, actual revenue was $43.39M
